



Cancer Immunotherapy and Immune-Related Adverse Events

Guest Editor:

Dr. Shaheen Khan

Department of Pathology, The
University of Texas Southwestern
Medical Center, Dallas, TX 75390-
9093, USA

Deadline for manuscript
submissions:

closed (15 July 2022)

Message from the Guest Editor

Dear Colleagues,

Cancer immunotherapy has shown remarkable success in the treatment of diverse cancer types. It utilizes the power of the immune system to recognize and attack cancer cells. The main types of cancer immunotherapies include immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, cytokines, immunomodulators, cancer vaccines, monoclonal antibodies, and oncolytic viruses. Although immunotherapy has emerged as a highly promising treatment option, a significant number of patients develop unpredictable and potentially severe immune-related adverse events (irAEs). For the optimal treatment and management of patients, it is critical to resolve the issues caused by immunotherapies, understand the mechanisms underlying irAEs, and identify biomarkers predictive of irAEs. Thus, the aim of this Special Issue is to highlight recent studies on immune-related adverse events associated with cancer immunotherapy. We will present original research and review articles addressing our current understanding of, novel studies on, and advancements pertaining to irAEs associated with cancer immunotherapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)